Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Q2 2025 Earnings Call Transcript
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Q2 2025 Earnings Call Transcript August 5, 2025Day One Biopharmaceuticals, Inc. beats earnings expectations.
Day One Biopharmaceuticals Inc. (DAWN)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Deerfield Management James E. Flynn | 3,723,131 | $24,200,352 | +26% | 0.44% |
| 2. | Alyeska Investment Group Anand Parekh | 3,012,187 | $19,579,216 | -26% | 0.07% |
| 3. | Vestal Point Capital Ryan Wilder | 3,000,000 | $19,500,000 | +16% | 1.03% |
| 4. | Braidwell LP Alex Karnal | 2,181,598 | $14,180,387 | -39% | 0.48% |
| 5. | Polar Capital Brian Ashford-Russell And Tim Woolley | 2,109,177 | $13,709,651 | -11% | 0.07% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $9.97 | 111,387 | $1,110,907.11 | 12,929,322 | 2023-10-20 | Filing | |
| $10.06 | 384,400 | $3,867,371.52 | 12,817,935 | 2023-10-19 | Filing | |
| $10.21 | 979,667 | $10,000,048.87 | 12,433,535 | 2023-10-18 | Filing | |
| $13.00 | 769,230 | $9,999,990.00 | 11,453,868 | 2023-06-09 | Filing | |
| $15.00 | 766,667 | $11,500,005.00 | 766,667 | 2022-06-17 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.26 | 3,927 | $24,574.77 | 35,161 | 2025-05-16 | Filing | |
| $6.26 | 4,552 | $28,485.96 | 47,136 | 2025-05-16 | Filing | |
| $6.26 | 4,282 | $26,796.33 | 265,231 | 2025-05-16 | Filing | |
| $6.26 | 13,964 | $87,385.32 | 145,737 | 2025-05-16 | Filing | |
| $11.96 | 4,370 | $52,278.31 | 252,638 | 2025-02-18 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 11,342,699 | $73,727,548 | 0% | |
| 2. | 9,830,431 | $63,897,804 | 0% | |
| 3. | 6,430,257 | $41,796,671 | 6.31% | |
| 4. | 6,176,495 | $40,147,219 | 0% | |
| 5. | 4,097,625 | $26,634,561 | 0.01% |
News See All
TimesSquare Capital U.S. Small Cap Growth Strategy Exited its Position in Day One Biopharmaceuticals Inc. (DAWN)
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” first-quarter 2025 investor letter.
JonesTrading Maintains Buy Rating on Day One Biopharmaceuticals (DAWN) Following Ojemda’s FDA Approval
The analyst supported the positive rating with Ojemda’s potential, which is a prescription medicine that treats certain brain tumor types.
H.C. Wainwright Maintains Buy Rating on Day One Biopharmaceuticals (DAWN), Keeps PT
The analyst based the rating update on the recent FDA approval of Ojemda (tovorafenib) for BRAF-altered, relapsed, or refractory pediatric low-grade glioma (pLGG).
10 Best Low Priced Biotech Stocks to Buy Now
On May 8, Michael Yee, Senior Biotech Analyst at Jefferies, appeared on CNBC to discuss how tariffs and policy risks are pressuring the biotech industry, while simultaneously iterating that low valuations...
10 Low Risk High Reward Stocks Set to Triple by 2030
The market is getting tough these days with increasing interest rates, tense world politics, and inconsistent economic conditions, and investors are constantly looking for opportunities.
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Q1 2025 Earnings Call Transcript
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Q1 2025 Earnings Call Transcript May 6, 2025Day One Biopharmaceuticals, Inc. beats earnings expectations.
10 Stocks Under $10 that Will Triple
As we delve into the discussion on stocks that will triple, we must shed light on the U.S.
Day One Biopharmaceuticals, Inc. (DAWN): A Bull Case Theory
We came across a bullish thesis on Day One Biopharmaceuticals, Inc. (DAWN) on Twitter by Pharmdca. In this article, we will summarize the bulls’ thesis on DAWN. Day One Biopharmaceuticals, Inc.
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Q4 2024 Earnings Call Transcript
Operator: Hello, ladies and gentlemen, and welcome to the Day One Biopharmaceuticals Fourth Quarter and Full Year 2024 Financial and Operating Results Conference Call.
Billionaire Hedge Funds
